Akten

Drug Overview

In the highly technical field of Ophthalmology, ensuring patient comfort during complex clinical procedures is a fundamental priority. For patients dealing with degenerative retinal conditions or severe ocular surface disease, the anxiety associated with eye procedures can be overwhelming. Akten represents a critical tool in managing this anxiety and pain. It is a highly effective medication classified under the Local Anesthetic drug class. By providing rapid, profound numbing of the ocular surface, this medication allows ophthalmologists to safely perform sight-saving interventions, such as the administration of a Biologic or laser therapy, without causing undue distress or discomfort to the patient.

This medication is meticulously formulated as a viscous gel, which increases its contact time with the eye, providing deeper and more sustained anesthesia compared to traditional liquid drops. It is strictly administered by healthcare professionals in a clinical or surgical setting.

• Generic Name: Lidocaine hydrochloride ophthalmic gel
• US Brand Names: Akten
• Drug Class: Local Anesthetic
• Route of Administration: Topical Ophthalmic Gel (applied directly to the ocular surface)
• FDA Approval Status: Fully FDA-approved for achieving profound ocular surface anesthesia during comprehensive ophthalmic procedures and minor surgical interventions.
  
  Discover Akten, an essential local anesthetic gel used to provide reliable ocular surface anesthesia during minor ophthalmic procedures.

What Is It and How Does It Work? (Mechanism of Action)

Akten is a specialized, highly viscous topical anesthetic. To understand how it works, we must examine the physiological generation and transmission of pain signals. When the surface of the eye is manipulated during a surgical procedure or injection, sensory nerve endings in the cornea and conjunctiva are stimulated. This stimulation causes the nerve cell membranes to depolarize, creating an action potential (an electrical signal) that travels rapidly along the nerve fibers to the brain, where it is perceived as sharp pain.

At the molecular level, the active ingredient, lidocaine hydrochloride, functions by blocking this electrical transmission. Lidocaine is an amide-type local anesthetic that acts directly on the voltage-gated sodium channels located within the neuronal cell membranes. When Akten is applied to the eye, the lidocaine molecules diffuse through the nerve membrane and bind to the intracellular portion of these sodium channels. This binding physically blocks the influx of sodium ions into the nerve cell. Without the rapid influx of sodium, the nerve membrane cannot depolarize, and an action potential cannot be generated or propagated.

Unlike a VEGF Inhibitor, which alters disease progression over months, this mechanism provides temporary, reversible blockade of nerve conduction. The unique gel formulation of Akten delays the washout of the drug by natural tear production, ensuring a concentrated, prolonged blockade that provides reliable anesthesia for the duration of the clinical procedure.

FDA-Approved Clinical Indications

Primary Indication: Ocular surface anesthesia for procedures

The primary, FDA-approved indication for Akten is to provide deep, reliable ocular surface anesthesia. This allows physicians to perform a wide variety of necessary clinical, diagnostic, and surgical ophthalmic procedures without causing pain to the patient.

Other Approved & Off-Label Uses

While it is an anesthetic, its application is directly tied to the management of severe ocular diseases.

• Primary Ophthalmology Indications:
  • Intravitreal Injection Anesthesia: Extensively used as a preparatory anesthetic before administering a Targeted Therapy (such as medications for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema) to stabilize the blood-retinal barrier and preserve visual acuity.
  • Glaucoma Management Procedures: Applied prior to performing advanced tonometry, gonioscopy, or selective laser trabeculoplasty (SLT) to manage intraocular pressure effectively.
  • Corneal Interventions: Utilized during the removal of corneal foreign bodies, suture removal following corneal transplants, or scraping of the corneal epithelium for diagnostic cultures.
  • Cataract Surgery: Used as a supplementary topical anesthetic during routine and complex cataract extractions.

Dosage and Administration Protocols

Proper application of this gel is critical to ensure deep anesthesia and prevent patient discomfort during invasive procedures. Healthcare professionals must adhere to strict sterile administration techniques. Hands must be washed, and gloves worn.

Indication	Standard Dose	Frequency
Standard Ophthalmic Procedures	2 drops of 3.5% gel to the ocular surface	Apply once, 5 to 10 minutes prior to the procedure.
Extensive/Prolonged Procedures	2 drops of 3.5% gel to the ocular surface	May reapply 1 additional drop after 5 minutes if needed.
Intravitreal Injection Prep	2 drops applied directly over the injection site	Apply once, 5 minutes prior to the injection.

Dose Adjustments: There are no specific dose adjustments required for pediatric use, though safety has not been fully established in neonates. For patients with prosthetic lenses (pseudophakia), the standard dose remains unchanged. The gel should be gently instilled into the conjunctival fornix or directly over the intended surgical site.

A qualified healthcare professional must individualize dosage.

Clinical Efficacy and Research Results

Clinical data (2020–2026) support the superior efficacy of lidocaine 3.5% gel (Akten) over aqueous anesthetic drops for ophthalmic procedures. While it does not affect BCVA or CRT, it is critical for enabling safe vision-preserving interventions.

Trials in intravitreal injections show lower VAS pain scores with the gel (mean 1.2/10) versus tetracaine drops (3.5/10). Onset occurs within ~5 minutes, with anesthesia lasting 20–30 minutes. Improved analgesia enhances patient stability, reducing movement-related risks such as ocular trauma, retinal injury, and intra-procedural IOP spikes

Safety Profile and Side Effects

There is currently no FDA Black Box Warning associated with Akten ophthalmic gel. However, like all local anesthetics, it must be handled with strict clinical oversight.

Common side effects (>10%)

• Conjunctival Hyperemia: Temporary redness of the white part of the eye immediately following application.
• Corneal Epithelial Changes: Mild, temporary clouding or superficial changes to the outermost layer of the cornea.
• Ocular Discomfort: A brief, transient stinging or burning sensation upon initial instillation before the numbing effect takes place.
• Headache: Mild, temporary headache following the procedure.

Serious adverse events

• Toxic Keratitis and Corneal Melting: If abused or used repeatedly outside of a clinical setting without supervision, local anesthetics can severely damage the corneal epithelium, leading to delayed healing, permanent scarring, and corneal melting.
• Systemic Toxicity: Though exceedingly rare with ophthalmic doses, severe systemic absorption can lead to central nervous system (CNS) toxicity, causing confusion, tremors, or cardiovascular collapse (bradycardia/hypotension).
• Endophthalmitis: While the drug itself does not cause infection, improper sterile technique during application prior to an injection can introduce bacteria into the eye.

Management Strategies: This medication is for in-clinic use only and is never dispensed to the patient for home use. Clinicians must use proper drop instillation techniques and monitor the patient for any signs of sudden pain or allergic reaction. The eye must be protected from physical rubbing while anesthetized to prevent accidental corneal abrasions.

Research Areas

Direct Clinical Connections

Current ophthalmic research is deeply investigating the interaction between topical anesthetics and the ocular surface environment. Because local anesthetics temporarily reduce the blink reflex and alter tear film dynamics, researchers are studying the short-term impact of lidocaine gel on goblet cell density and epithelial barrier integrity. Understanding these dynamics is crucial for patients with severe Dry Eye Disease who require frequent procedures, ensuring that the necessary anesthesia does not exacerbate underlying chronic ocular surface disease.

Generalization

Between 2020–2026, research has focused on improving safety and comfort through preservative-free lidocaine gel to reduce corneal toxicity from repeated use. Studies also explore sustained-release bioabsorbable anesthetic systems for prolonged pain control during surgery, minimizing the need for repeated applications.

Disclaimer: The research discussed regarding the short-term impact of lidocaine gel on goblet cell density and epithelial barrier integrity, as well as the development of sustained-release bioabsorbable anesthetic systems, is currently in the investigational or preclinical phase and is not yet applicable to standard clinical practice. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

Before administering Akten, a comprehensive clinical evaluation of the ocular surface is mandatory.

• Baseline Diagnostics: An assessment of Baseline Visual Acuity and a thorough Slit-lamp exam to evaluate the health of the corneal epithelium. Pre-existing corneal abrasions must be noted, as anesthetics can delay cellular healing.
• Ocular Imaging: If the anesthetic is being used prior to an intravitreal injection, baseline Optical Coherence Tomography (OCT) is performed before the gel is applied to ensure clear imaging without gel artifact interference.
• Screening: A strict review of the patient’s medical history is required to screen for any known hypersensitivity to amide-type local anesthetics, history of severe cardiovascular disease, or active herpes simplex keratitis.

Monitoring and Precautions

• Vigilance: Following the procedure, clinical vigilance is required. The patient’s eye remains numb for 20 to 30 minutes. Staff must monitor the patient to ensure they do not inadvertently scratch or rub their eye while they cannot feel it.
• Lifestyle: After leaving the clinic, patients should employ UV protection (sunglasses) if they also received dilating drops. Eyelid hygiene (lid scrubs) should be paused for 24 hours if an injection was performed to prevent introducing bacteria to the injection site.
• “Do’s and Don’ts” list:
  • DO report any escalating eye pain or sudden loss of vision to your doctor immediately after you return home.
  • DO use highly lubricating, preservative-free artificial tears if your eye feels scratchy once the anesthesia wears off.
  • DON’T rub, press, or touch your eye for at least one hour following the procedure to prevent accidental injury to the numb cornea.
  • DON’T wear contact lenses until your physician has explicitly cleared you to do so, typically 24 to 48 hours post-procedure.

Legal Disclaimer

The medical information provided in this comprehensive guide is intended for educational and general informational purposes only. It does not constitute professional medical advice, clinical diagnosis, or a formalized treatment plan. Always consult directly with a qualified healthcare provider or a board-certified specialist ophthalmologist regarding any specific questions you may have about a medical condition, scheduled diagnostic procedures, or prescription medications. Never disregard professional medical advice or delay in seeking it because of information provided on this clinic website